Your browser doesn't support javascript.
loading
Reversing the Inflammatory Process-25 Years of Tumor Necrosis Factor-α Inhibitors.
Muth, Katharina N; Rech, Juergen; Losch, Florian O; Hoerning, André.
Affiliation
  • Muth KN; Medical Affairs, Hexal AG, 83607 Holzkirchen, Germany.
  • Rech J; Department of Internal Medicine III, Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany.
  • Losch FO; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany.
  • Hoerning A; Medical Affairs, Hexal AG, 83607 Holzkirchen, Germany.
J Clin Med ; 12(15)2023 Jul 31.
Article de En | MEDLINE | ID: mdl-37568441
ABSTRACT
Immune-mediated inflammatory diseases, such as rheumatoid arthritis, psoriatic arthritis, peripheral and/or axial spondyloarthritis, Crohn's disease, and ulcerative colitis, are characterized by molecular and cellular changes in the immune system. Due to the systemic nature of these diseases, organs such as the liver or cardiovascular system are often affected by the inflammatory process. Tumor necrosis factor-α inhibitor therapy reduces the activation of pro-inflammatory signaling cascades, mitigates the chronic inflammatory process by restoring cellular balance, and alleviates clinical consequences, such as pain and tissue damage.
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: J Clin Med Année: 2023 Type de document: Article Pays d'affiliation: Allemagne

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: J Clin Med Année: 2023 Type de document: Article Pays d'affiliation: Allemagne